Lean on our expertise across the entire product cycle to navigate your ever-changing industry with confidence, and make insight generation easy.
Craft data-driven commercial strategies that resonate with your diverse stakeholders, from patients and caregivers to providers, payers, hospital stakeholders, and more.
Address the unique challenges you face (including the treatment of patients with rare and ultra-rare diseases) complicated market access and distribution, and more.
Generate healthcare insights that improve patient outcomes, meet provider needs, and assimilate growing regulatory pressures through our evidence-based, innovative research solutions.
Tracking the performance of a revamped messaging campaign required developing a system to measure…
Launching a novel therapy for a rare disease involved building a robust system for continuous…
Benchmarking against competitors required quantitative insights that enabled performance tracking…
Establishing baseline metrics for a new biosimilar involved comprehensive quantitative research to…
Trusted and knowledgeable would be two words I’d use to describe KJT. We have a very good strategic relationship – they work with us and not against us.
Having these insights allow us to quickly and confidently make decisions and prioritize opportunities.
KJT is more than just an executor of research – they’re a true strategic partner. We have several continuous ongoing projects with them and they’re always smooth and seamless to work with.
KJT is more than just a vendor, they’re a partner. They always offer a tailored approach and are very responsive.
We have a good and comfortable relationship with KJT. They have a deep understanding of our market. Pricing is fair, and the output is good. You just know what you’re going to get.
A panel discussion that bridges the worlds between insights, advertising, digital solutions, advocacy and more.
Focusing in on the patients with rare diseases, we cover the importance of representing and elevating the patient voice and provide solutions to overcome the unique hurdles of this space. We also discuss the future use of Generative AI, including considerations for ethical and responsible use when aiming to further understand, and communicate to, patients with rare diseases.
AI-moderated interviewing emerged as an extension of the shift to online qual accelerated by COVID….
In rare disease care, communication between patients and physicians is often fragmented, leading to…
In rare and orphan diseases, the patient journey is often described as a “diagnostic odyssey.”…
When planning a real-world evidence (RWE) study, teams naturally focus on design,…
In pharmaceutical market research, one element remains consistently crucial: participant…
Publishing real-world evidence (RWE) research involves a comprehensive journey of strategic…
Understanding what goes on in the exam room between patients and HCPs remains a critical yet…
Artificial Intelligence is reshaping how life sciences organizations gather insights, understand…
Real-world evidence (RWE) is only as meaningful as the perspectives it includes. While healthcare…
Synthetic data is not new to market research, and the healthcare insights industry is starting to…
